Cascadian Therapeutics, Inc. (NASDAQ:CASC) issued its earnings results on Tuesday. The biopharmaceutical company reported ($0.30) earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.36) by $0.06, Briefing.com reports. During the same period last year, the business earned ($1.57) earnings per share.

Shares of Cascadian Therapeutics (CASC) traded down 4.026% on Thursday, reaching $3.695. The company had a trading volume of 183,935 shares. The firm’s market cap is $181.96 million. Cascadian Therapeutics has a one year low of $0.84 and a one year high of $6.72. The company has a 50-day moving average price of $3.93 and a 200-day moving average price of $4.02.

WARNING: “Cascadian Therapeutics, Inc. (CASC) Issues Quarterly Earnings Results” was originally posted by Daily Political and is the sole property of of Daily Political. If you are reading this piece on another domain, it was stolen and reposted in violation of US and international trademark and copyright laws. The original version of this piece can be read at https://www.dailypolitical.com/2017/08/10/cascadian-therapeutics-inc-casc-issues-quarterly-earnings-results.html.

Several equities research analysts have weighed in on CASC shares. ValuEngine lowered Cascadian Therapeutics from a “sell” rating to a “strong sell” rating in a research report on Friday, June 2nd. Zacks Investment Research raised Cascadian Therapeutics from a “hold” rating to a “buy” rating and set a $4.50 price target on the stock in a report on Monday, July 17th. Cantor Fitzgerald reissued a “hold” rating and set a $4.00 price target on shares of Cascadian Therapeutics in a report on Wednesday, May 10th. Cowen and Company reissued a “buy” rating on shares of Cascadian Therapeutics in a report on Tuesday, May 9th. Finally, BTIG Research assumed coverage on Cascadian Therapeutics in a report on Friday, April 21st. They set a “buy” rating on the stock. One investment analyst has rated the stock with a sell rating, one has issued a hold rating and four have issued a buy rating to the stock. The stock has an average rating of “Buy” and a consensus target price of $6.17.

About Cascadian Therapeutics

Cascadian Therapeutics, Inc, formerly Oncothyreon Inc, is a clinical-stage biopharmaceutical company. The Company focuses on the development of therapeutic products for the treatment of cancer. The Company’s clinical-stage product candidate includes ONT-380, an orally active and selective small-molecule human epidermal growth factor receptor (HER) 2 inhibitor.

Earnings History for Cascadian Therapeutics (NASDAQ:CASC)

Receive News & Ratings for Cascadian Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cascadian Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.